Lisata Therapeutics (NASDAQ:LSTA) Trading 1.4% Higher – Still a Buy?

Lisata Therapeutics, Inc. (NASDAQ:LSTA) rose 1.4% during trading on Wednesday . The company traded as high as $2.98 and last traded at $2.98. Approximately 45,386 shares traded hands during trading, an increase of 215% from the average daily volume of 14,403 shares. The stock had previously closed at $2.94.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and set a $15.00 target price on shares of Lisata Therapeutics in a research report on Wednesday, December 11th.

Lisata Therapeutics Trading Up 2.0 %

The stock’s 50 day moving average is $2.83 and its 200 day moving average is $3.04. The stock has a market capitalization of $30.56 million, a price-to-earnings ratio of -1.45 and a beta of 1.14.

Lisata Therapeutics (NASDAQ:LSTA) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.59) EPS for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.16. During the same period in the previous year, the company earned ($0.65) earnings per share. On average, sell-side analysts anticipate that Lisata Therapeutics, Inc. will post -2.66 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Lisata Therapeutics stock. Dimensional Fund Advisors LP raised its position in shares of Lisata Therapeutics, Inc. (NASDAQ:LSTA) by 48.2% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,336 shares of the company’s stock after purchasing an additional 5,639 shares during the period. Dimensional Fund Advisors LP owned 0.21% of Lisata Therapeutics worth $60,000 as of its most recent SEC filing. 8.94% of the stock is currently owned by institutional investors.

Lisata Therapeutics Company Profile

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.